This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions
Zhixiong Zhong
Meizhou People's Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-9997-5339
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
The purpose of this study was to study the relationship between ALK&ROS1 gene rearrangement, EGFR mutation, non-ALK&ROS1/EGFR and their clinical characteristics in non-small cell lung cancer (NSCLC) patients to distinguish these different types.
Methods
Both ALK&ROS1 gene rearrangements and EGFR mutations testing were performed in 461 NSCLC patients. The clinical characteristics and associated pulmonary abnormalities were investigated.
Results
Of the 461 patients studied, we identified 175 cases with EGFR mutations (38.0%, 175/461). ALK gene fusions were identified in 33 cases (33/461, 7.2%) and ROS1 gene fusions were identified in 9 cases (9/461, 1.9%). In the EGFR-positive group, the majority were female (50.9%, P < 0.001), non-smoking (76.6%, P < 0.001), adenocarcinoma (90.9%, P < 0.001) patients. Compared with the non-ALK&ROS1/EGFR group, the significant differences in ALK&ROS1-positive group were: younger (P < 0.001), the majority were female (52.4%, P < 0.001), non-smoking (66.7%, P = 0.001), adenocarcinoma (90.5%, P = 0.002) patients, appeared lymphangitic was more (23.8%, P = 0.044) and emphysema was less (9.5%, P < 0.001). The NSCLC patients with exon 19 deletion (74.7%) and L858R (86.4%) most were non-smokers, while patients with L861Q (62.5%) and G719 × (66.7%) most were smokers.
Conclusions
NSCLC with EGFR mutation and ALK&ROS1 gene rearrangement were more likely to occur in young, non-smoking women. Patients with ALK&ROS1 gene rearrangements and EGFR mutations were less likely to develop emphysema.
Keywords
EGFR, ALK, ROS1, Clinical characteristics
Figure 1
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 20 May, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Research
Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions
Zhixiong Zhong
Meizhou People's Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-9997-5339
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 20 May, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
The purpose of this study was to study the relationship between ALK&ROS1 gene rearrangement, EGFR mutation, non-ALK&ROS1/EGFR and their clinical characteristics in non-small cell lung cancer (NSCLC) patients to distinguish these different types.
Methods
Both ALK&ROS1 gene rearrangements and EGFR mutations testing were performed in 461 NSCLC patients. The clinical characteristics and associated pulmonary abnormalities were investigated.
Results
Of the 461 patients studied, we identified 175 cases with EGFR mutations (38.0%, 175/461). ALK gene fusions were identified in 33 cases (33/461, 7.2%) and ROS1 gene fusions were identified in 9 cases (9/461, 1.9%). In the EGFR-positive group, the majority were female (50.9%, P < 0.001), non-smoking (76.6%, P < 0.001), adenocarcinoma (90.9%, P < 0.001) patients. Compared with the non-ALK&ROS1/EGFR group, the significant differences in ALK&ROS1-positive group were: younger (P < 0.001), the majority were female (52.4%, P < 0.001), non-smoking (66.7%, P = 0.001), adenocarcinoma (90.5%, P = 0.002) patients, appeared lymphangitic was more (23.8%, P = 0.044) and emphysema was less (9.5%, P < 0.001). The NSCLC patients with exon 19 deletion (74.7%) and L858R (86.4%) most were non-smokers, while patients with L861Q (62.5%) and G719 × (66.7%) most were smokers.
Conclusions
NSCLC with EGFR mutation and ALK&ROS1 gene rearrangement were more likely to occur in young, non-smoking women. Patients with ALK&ROS1 gene rearrangements and EGFR mutations were less likely to develop emphysema.
Figure 1